Manages acute pain severe enough to require an opioid analgesic. ANDA 90964, held by Hikma. Oxymorphone Hydrochloride.
As of Nov 16, 2026, ANDA 90964 (Oxymorphone Hydrochloride), held by Hikma, was first approved by FDA on Sep 27, 2010, with 11 approved supplements and 0 published complete response letters.
Oxymorphone hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including oxymorphone hydrochloride tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 27, 2010 | Original application | Approved | None posted |
| Oxymorphone Hydrochloride5MG · tablet;oral | Oxymorphone Hydrochloride | Rx |
| Oxymorphone Hydrochloride10MG · tablet;oral | Oxymorphone Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 16REMS | Approved | None posted |
| Dec 22, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 10, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 12REMS | Approved | None posted |
| Jan 19, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 4, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 8, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 8, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 8, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 6REMS | Approved | None posted |
| Aug 25, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 27, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters